載入...
The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a synergistic antitumor effect in preclinical models. This article presents the results of the phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
Remedium Group LLC
2021-06-01
|
| 叢編: | Медицинский совет |
| 主題: | |
| 在線閱讀: | https://www.med-sovet.pro/jour/article/view/6209 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|